why choose us

First received: August 28, 2022

Clinical Trial: Cardiotoxicities in Patients Receiving BTKi

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Chronic Lymphocytic Leukemia

Study Type: OBSERVATIONAL


Official Title: A Multicenter, Prospective Cohort Study for Detection of Cardiotoxicities in Patients Receiving Ibrutinib or Acalabrutinib for CLL

Brief Summary: This is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with CLL patients who are initiating treatment with a Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or acalabrutinib.

Read more